You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Optimizing Cytomegalovirus Infection Prevention for Allogenic Hematopoietic Stem Cell Transplantation Patients

  • Authors: Gizelle Popradi, MD; Sarah Shalhoub, MD; Genovefa Papanicolaou, MD; Per Ljungman, MD
  • CME / ABIM MOC Released: 3/23/2023
  • Valid for credit through: 3/23/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematology/oncology specialists, infectious disease (ID)/HIV specialists, and critical care specialists.

The goal of this activity is for the learner to be better able to understand and adopt CMV prevention strategies in patients undergoing allogenic HSCT.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mechanisms of action of the various therapies used in the treatment and prevention, including assessment of risk in CMV active infection and disease, after allogeneic HSCT
    • Real-world evidence on the benefits and limitations of CMV antiviral management strategies post-allogeneic HSCT
  • Have greater competence related to
    • Clinical guideline recommendations for the treatment and prevention of CMV infection in post-allogeneic HSCT patients


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Gizelle Popradi, MD

    Director of Hemopoietic Stem Cell Transplant program
    McGill University Hospital
    Montreal, Quebec, Canada


    Gizelle Popradi, MD, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie Inc.; Avir Pharma; Amgen, Inc.; Bristol Myers Squibb Company; Gilead Sciences, Inc.; Jazz Pharmaceuticals, Inc.; Kite Pharma, Inc.; Kyowa Kirin Pharmaceutical Development, Inc.; Mallinckrodt; Merck; Novartis; Pfizer, Inc.; Seagen Inc.; Sanofi; SERVIER; Taiho Pharmaceutical Co., Ltd.; Takeda
    Speaker or member of speakers bureau for: Amgen, Inc.; Merck; Novartis; Pfizer, Inc.; Sanofi; Seagen Inc. 
    Research funding from: AbbVie Inc.; Equilium Inc; Syndax Pharmaceuticals, Inc.

  • Sarah Shalhoub, MD

    Transplant Infectious Diseases
    Department of Medicine
    Assistant Professor
    London Health Sciences Centre
    Western University
    London, Ontario, Canada


    Sarah Shalhoub, MD, has the following relevant financial relationships: 
    Research funding from: I am a site investigator for the Novation-1 trial: A randomized, double-blind, placebo controlled, phase III study to evaluate the safety and efficacy of aerosolized novaferon + SOC vs. placebo + SOC in hospitalized adult patients with moderate to severe COVID-19.

  • Genovefa Papanicolaou, MD

    Transplant ID Physician
    Memorial Sloan Kettering Cancer Center
    New York, New York, United States


    Genovefa Papanicolaou, MD, has the following relevant financial relationships: 
    Consultant or advisor for: AlloVir; Astellas Pharma, Inc.; Cidara; CSL Behring; Merck; Octapharma; SymBio Pharmaceuticals Limited; Takeda
    Research funding from: Merck; Takeda

  • Per Ljungman, MD

    Professor Emeritus of Hematology
    Karolinska Institutet
    Senior Physician
    Department of Cellular Therapy, Allogeneic Stem Cell Transplantation and Hematology
    Karolinska University Hospital
    Stockholm, Sweden


    Per Ljungman, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Gilead
    Speaker or member of speakers bureau for: Biotest; Bristol Myers Squibb Company; Gilead Sciences, Inc. InMed Medical Communications China; Merck Sharp & Dohme; Moderna, Inc.; Takeda 
    Research funding from: AlloVirJanssen (former); Merck Sharp & Dohme (former); Takeda (former) 
    Contracted researcher for: Blueprint Pharmaceuticals (DSMB member); Enanta Pharmaceuticals, Inc. (DSMB chair); Octapharma (DSMB chair) 


  • Maya Khalaf, MSc

    Medical Education Director, WebMD Global, LLC


    Maya Khalaf, MSc, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50  AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Optimizing Cytomegalovirus Infection Prevention for Allogenic Hematopoietic Stem Cell Transplantation Patients

Authors: Gizelle Popradi, MD; Sarah Shalhoub, MD; Genovefa Papanicolaou, MD; Per Ljungman, MDFaculty and Disclosures

CME / ABIM MOC Released: 3/23/2023

Valid for credit through: 3/23/2024, 11:59 PM EST


Contents of This CME Activity

All sections of this activity are required for credit.

Understanding CMV Infection Risk in Allogeneic HSCT

In addition to the clinical burden, did you know that CMV infection after allogeneic HSCT is associated with a significant economic burden?
Gizelle Popradi, MD

Approaches to Prophylactic and Preemptive CMV Strategies

Did you know that approximately 80% of CMV-seropositive recipients are at risk for significant CMV viremia and disease?
Sarah Shalhoub, MD

What Have We Learned From the Real-World Evidence?

Did you know that real-world outcomes of currently available standard of care demonstrated significant reductions in CMV disease and mortality?
Genovefa Papanicolaou, MD

Guideline Recommendations for the Prevention of CMV Infection in Patients Receiving Allogeneic HSCT

What are the treatment considerations for the prevention of CMV infection after allogeneic HSCT?
Per Ljungman, MD

Learning Feedback Questions

Please answer these questions to complement your learning experience.

  • Print